Evercore ISI has upgraded Dova Pharmaceuticals (NASDAQ:DOVA) to Outperform, from In-Line.
That joins a mostly bullish set of covering analysts.
Sell-side analysts rate the stock an Outperform on average, while it has a Quant Rating of Neutral.
At last check shares were up 2.1% postmarket.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.